Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission

  • Yoshiyuki OgawaEmail author
  • Kunio Yanagisawa
  • Chiaki Naito
  • Hideki Uchiumi
  • Takuma Ishizaki
  • Hiroaki Shimizu
  • Fumito Gohda
  • Masahiro Ieko
  • Akitada Ichinose
  • Hiroshi Handa
Original Article


Acquired hemophilia A (AHA) is a rare, life-threatening bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Immunosuppressive therapy for AHA aims to arrest bleeding by eliminating FVIII inhibitors. Factor VIII activity overshoot after complete remission (CR) has been reported anecdotally, but details remain unclear. We retrospectively analyzed data from 17 patients with AHA who achieved CR under immunosuppressive therapy between 2009 and 2019 at Gunma University Hospital. FVIII activity overshoot was defined as ≥ 150%. All 17 patients had low FVIII activity (median 2.1%; range < 1.0–8.9%) due to FVIII inhibition (median 14.7 BU/mL; range 2.0–234.0) and all achieved CR within a median of 39 (range 19–173) days. Overshoot occurred in 11 (64.7%) patients and maximal FVIII activity reached > 200% in six of them. The median duration from CR to overshoot was 13 (range 0–154) days. The FVIII overshoot was transient (72.7%) or persistent (27.3%). Venous thromboembolism developed as a complication of overshoot in one patient due to iliac vein compression by a massive hematoma. Overshoot of FVIII activity after CR occurs more frequently than previously expected in patients with AHA.


Acquired hemophilia A Coagulation factor VIII (FVIII) FVIII inhibitor Overshoot of FVIII activity Immunosuppressive therapy 



We are grateful to the patients who participated in this study.

Author contributions

YO, AI, MI and HH designed the study. YO, KY, CN, HU, TI, HS, FG, and HH evaluated patients. YO, KY and CN analyzed the data. YO, AI and HH prepared the manuscript, which all the authors reviewed.

Compliance with ethical standards

Conflicts of interest

None of the authors have any conflicts of interest to declare.


  1. 1.
    Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45:200–3.CrossRefGoogle Scholar
  2. 2.
    Collins PW. Management of acquired haemophilia A. J Thromb Haemost. 2011;9(Suppl 1):226–35.CrossRefGoogle Scholar
  3. 3.
    Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano ME, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010;3:161.CrossRefGoogle Scholar
  4. 4.
    Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109:1870–7.CrossRefGoogle Scholar
  5. 5.
    Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R. A population based, unselected, consecutive cohort of patients with acquired hemophilia A. Br J Haematol. 2004;124:86–90.CrossRefGoogle Scholar
  6. 6.
    Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987;147:1077–81.CrossRefGoogle Scholar
  7. 7.
    Baudo F, Collins P, Huth-Kühne A, Lévesque H, Marco P, Nemes L, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012;120:39–46.CrossRefGoogle Scholar
  8. 8.
    Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004;103:4424–8.CrossRefGoogle Scholar
  9. 9.
    Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol. 2007;63:47–52.CrossRefGoogle Scholar
  10. 10.
    Ogawa Y, Yanagisawa K, Uchiumi H, Ishizaki T, Mitsui T, Gouda F, et al. Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan. Int J Hematol. 2017;106:82–9.CrossRefGoogle Scholar
  11. 11.
    Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94:566–75.CrossRefGoogle Scholar
  12. 12.
    Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:612.PubMedGoogle Scholar
  13. 13.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.CrossRefGoogle Scholar
  14. 14.
    Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimerization and propeptide cleavage in the binding and stabilization of factor VIII. J Biol Chem. 1991;266:21948–55.PubMedGoogle Scholar
  15. 15.
    Senis YA, Richardson M, Tinlin S, Maurice DH, Giles AR. Changes in the pattern of distribution of von Willebrand factor in rat aortic endothelial cells following thrombin generation in vivo. Br J Haematol. 1996;93:195–203.CrossRefGoogle Scholar
  16. 16.
    Galbusera M, Zoja C, Donadelli R, Paris S, Morigi M, Benigni A, et al. Fluid shear stress modulates von Willebrand factor release from human vascular endothelium. Blood. 1997;90:1558–644.CrossRefGoogle Scholar
  17. 17.
    Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69:1691–5.CrossRefGoogle Scholar
  18. 18.
    Holmberg L, Nilsson IM. AHF related protein in clinical praxis. Scand J Haematol. 1974;12:221–31.CrossRefGoogle Scholar
  19. 19.
    Bloom AL. The biosynthesis of factor VIII. Clin Haematol. 1979;8:53–77.PubMedGoogle Scholar
  20. 20.
    Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol. 2001;21:731–8.CrossRefGoogle Scholar
  21. 21.
    Tiede A, Worster A. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. Ann Hematol. 2018;97:1889–901.CrossRefGoogle Scholar
  22. 22.
    Amano K, Seita I, Higasa S, Sawada A, Kuwahara M, Shima M. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data. Haemophilia. 2017;23:50–8.CrossRefGoogle Scholar
  23. 23.
    Ashrani AA, Reding MT, Greeno EW, Shet A, Key NS. Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia. Haemophilia. 2002;8:56–8.CrossRefGoogle Scholar
  24. 24.
    Maral S, Bakanay SM, Dilek I. Acquired hemophilia with thrombosis in a cancer patient: an unusual presentation. Blood Coagul Fibrinol. 2018;29:129–30.CrossRefGoogle Scholar
  25. 25.
    Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–5.CrossRefGoogle Scholar
  26. 26.
    Kraaijenhagen RA, in’t Anker PS, Koopman MMW, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83:5–9.CrossRefGoogle Scholar
  27. 27.
    Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457–62.CrossRefGoogle Scholar
  28. 28.
    Ryland JK, Lawrie AS, Mackie IJ, Machin SJ. Persistent high factor VIII activity leading to increased thrombin generation—a prospective cohort study. Thromb Res. 2012;129:447–52.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2020

Authors and Affiliations

  • Yoshiyuki Ogawa
    • 1
    • 2
    Email author
  • Kunio Yanagisawa
    • 1
  • Chiaki Naito
    • 1
  • Hideki Uchiumi
    • 1
    • 3
  • Takuma Ishizaki
    • 1
  • Hiroaki Shimizu
    • 1
  • Fumito Gohda
    • 4
  • Masahiro Ieko
    • 2
    • 5
  • Akitada Ichinose
    • 2
    • 6
  • Hiroshi Handa
    • 1
  1. 1.Department of HematologyGunma University Graduate School of MedicineMaebashiJapan
  2. 2.The Japanese Collaborative Research Group (JCRG) on Acquired Coagulopathies Supported by the Japanese Ministry of Health, Labour and WelfareYamagataJapan
  3. 3.Hidaka-Kai Shirane ClinicNumataJapan
  4. 4.Department of Internal MedicineNational Hospital Organization Takasaki General Medical CenterTakasakiJapan
  5. 5.Department of Internal Medicine, School of DentistryHealth Sciences University of HokkaidoIshikari-TonetsuJapan
  6. 6.Department of Molecular Patho-Biochemistry and Patho-BiologyYamagata University School of MedicineYamagataJapan

Personalised recommendations